Filing Details
- Accession Number:
- 0001127602-21-015223
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-04 13:00:00
- Reporting Period:
- 2021-04-30
- Accepted Time:
- 2021-05-04 16:43:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 816956 | Conmed Corp | CNMD | Electromedical & Electrotherapeutic Apparatus (3845) | 160977505 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1238334 | S Daniel Jonas | C/O Conmed Corp 11311 Concept Boulevard Largo FL 33773 | Evp Legal Affairs,Gen. Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-04-30 | 700 | $41.93 | 14,506 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-30 | 600 | $142.58 | 13,906 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-30 | 100 | $143.30 | 13,806 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-04-30 | 10,000 | $41.93 | 23,806 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-30 | 10,000 | $141.08 | 13,806 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-04-30 | 5,000 | $59.96 | 18,806 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-30 | 5,000 | $142.00 | 13,806 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-05-03 | 4,176 | $41.93 | 17,982 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-05-03 | 4,176 | $145.59 | 13,806 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Options To Purchase Common Stock | Disposition | 2021-04-30 | 700 | $0.00 | 700 | $41.93 |
| Common Stock | Options To Purchase Common Stock | Disposition | 2021-04-30 | 10,000 | $0.00 | 10,000 | $41.93 |
| Common Stock | Options To Purchase Common Stock | Disposition | 2021-04-30 | 5,000 | $0.00 | 5,000 | $59.96 |
| Common Stock | Options To Purchase Common Stock | Disposition | 2021-05-03 | 4,176 | $0.00 | 4,176 | $41.93 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 19,176 | 2027-03-01 | No | 4 | M | Direct | |
| 9,176 | 2027-03-01 | No | 4 | M | Direct | |
| 22,000 | 2028-03-01 | No | 4 | M | Direct | |
| 5,000 | 2027-03-01 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.10 to $142.725. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.00 to $141.17. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.52 to $145.61. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
Billionaire Hedge Funds
